Last updated: July 26, 2026
Executive summary: Public court records for Bayer Intellectual Property GMBH v. Taro Pharmaceutical Industries Ltd. under case no. 1:17-cv-00462 are not provided in the input. Without the underlying complaint, claim chart, Markman rulings, operative scheduling orders, docket events, and any settlement or final judgment entries, a complete and accurate litigation summary cannot be produced.
What patents did Bayer Intellectual Property GMBH assert against Taro in 1:17-cv-00462?
No asserted patent list, patent numbers, or asserted claims are included in the provided information. A litigation analysis that ties infringement allegations to specific Orange Book-listed patents or 35 U.S.C. § 271(e)(2) theories cannot be completed.
Was this an ANDA Paragraph IV case under 35 U.S.C. § 271(e)(2)?
No ANDA number, FDA reference product, or Paragraph IV notice details are provided.
Which drug and active ingredient were at issue?
The input does not specify the Bayer product, active ingredient, or dosage form, so the scope of asserted subject matter cannot be mapped.
What did Taro argue in its defenses in 1:17-cv-00462?
No responsive pleadings, invalidity theories (anticipation/obviousness/§112), noninfringement arguments, or procedural defenses are included in the input.
What were the likely invalidity bases (anticipation, obviousness, §112, nonstatutory subject matter)?
No invalidity content is provided.
What were the likely claim-construction disputes?
No Markman schedule, claim terms, or construction outcomes are provided.
How has the case progressed procedurally (motions, claim construction, trial, or dismissal) in 1:17-cv-00462?
No docket timeline or milestone events are provided (for example: complaint filing, motion to dismiss, amended complaint, Markman order, summary judgment, trial setting, or final judgment).
Key procedural dates and docket events
None are provided.
Were there stays pending USPTO reexamination, IPR, or concurrent PTO proceedings?
No IPR/PGR/reexamination references are included.
What is the current status of Bayer v. Taro 1:17-cv-00462 (active, stayed, settled, or resolved)?
The input does not include current docket status or any settlement/judgment entry. A status statement and enforcement posture cannot be produced.
Did the parties enter a settlement agreement affecting generic launch dates?
No settlement details are provided.
Was there a stipulated dismissal without prejudice or with prejudice?
No dismissal outcome is provided.
What generic entry risks does 1:17-cv-00462 create for Taro and competitors?
A generic entry risk analysis requires: (1) the specific patents-in-suit, (2) infringement/validity rulings or settlement terms, and (3) the Orange Book exclusivity and remaining expiration dates tied to the asserted patents. None of these inputs are provided.
When does the asserted patent estate expire (patents and any PTA/PTE)?
No patent expiration dates are provided.
What is the risk for design-around, launch-at-risk, or later generic entry?
No operative claims, design-around pathways, or enforceable injunction posture is provided.
What is the Orange Book status of the patents asserted in 1:17-cv-00462?
No Orange Book patent identifiers, listed claims, or regulatory status are included.
Which Orange Book patents were listed for the reference drug?
Not provided.
Do any exclusivities (5-year NCE, 7-year, pediatric exclusivity) apply?
Not provided.
How does this litigation compare with other Bayer vs. generic cases involving Taro or related parties?
No comparative record, similar Bayer/Taro disputes, or cross-case themes are provided.
Which companies are the main competitors affected by this dispute?
Not provided.
Are there parallel cases in other districts or consolidated actions?
Not provided.
What does the patent portfolio analysis imply for enforceability and licensing leverage in 1:17-cv-00462?
A portfolio analysis requires the asserted claim sets and their validity/enforcement history. Those details are not provided.
How strong is the asserted patent estate (based on available prior art, prosecution history, and prior litigations)?
Not provided.
What licensing positions would typically follow from this posture?
Not provided.
Key Takeaways
- No litigation-specific record (asserted patents, docket events, rulings, settlement, or final disposition) is included in the provided input for Bayer Intellectual Property GMBH v. Taro Pharmaceutical Industries Ltd. (1:17-cv-00462).
- A litigation summary and analysis cannot be produced to a high-integrity standard without the underlying court filings and docket outcomes.
FAQs
- What patents were in-suit in Bayer v. Taro 1:17-cv-00462?
- Was 1:17-cv-00462 an ANDA Paragraph IV challenge, and what FDA submission triggered it?
- What claim terms were construed in the Markman phase for 1:17-cv-00462?
- Did the parties settle, and what were the terms tied to generic launch?
- Which Orange Book patents and exclusivities governed the commercial timeline in 1:17-cv-00462?
References
- Not available from the provided input.
